Transforming growth factor-β is activated by plasmin and inhibits smooth muscle cell death in human saphenous vein

Journal of Vascular Research

Volumn 42, Issue 3, 2005, Pages 247-254

  George, Sarah J ^a   Johnson, Jason L ^a   Smith, Melanie A ^a   Angelini, Gianni D ^a   Jackson, Christopher L ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Apoptosis; Coronary artery bypass graft; Plasmin; Saphenous vein; Smooth muscle; Transforming growth factor

Indexed keywords

AMILORIDE; ANTIBODY; N ACETYLLYSINE METHYL ESTER; NEUTRALIZING ANTIBODY; PLASMIN; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ALPHA ACETYLLYSINE METHYL ESTER; ALPHA-ACETYLLYSINE METHYL ESTER; DRUG DERIVATIVE; LYSINE; UROKINASE;

APOPTOSIS; ARTICLE; BYPASS SURGERY; CELL CULTURE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; INTIMA; PRIORITY JOURNAL; PROTEIN FUNCTION; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; TUNICA MEDIA; CELL DIVISION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

AMILORIDE; ANTIBODIES; APOPTOSIS; CELL DEATH; CELL DIVISION; HUMANS; LYSINE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; ORGAN CULTURE TECHNIQUES; PLASMIN; SAPHENOUS VEIN; TRANSFORMING GROWTH FACTOR BETA; URINARY PLASMINOGEN ACTIVATOR;

EID: 20644434188     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085657     Document Type: Article

References (31)

1. Angelini GD, Newby AC: The future of human saphenous vein as a coronary artery bypass conduit. Eur Heart J 1989;10:273-280.
2. Dilley RJ, McGeachie JK, Pendergast FJ: A review of the histologic changes in vein-to-artery grafts, with particular reference to arterial hyperplasia. Arch Surg 1988;123:691-696.
3. Fuchs JCA, Mitchener JS, Hagen PO: Post-operative changes in autologous vein grafts. Ann Surg 1978;188:1-15.
4. Soyombo AA, Angelini GD, Bryan AJ, Jasani B, Newby AC: Intimai proliferation in an organ culture of human saphenous vein. Am J Pathol 1990;137:1401-1410.
5. George SJ, Williams A, Newby AC: An essential role for platelet-derived growth factor in neointima formation in human saphenous vein in vitro. Atherosclerosis 1996;120:227-240.
6. Sporn MB, Robert AM: Transforming growth factor-β: Recent progress and new challenges. J Cell Biol 1992;111:757-763.
7. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB: Latent transforming growth factor-β: Structural features and mechanisms of activation. Kidney Int 1997;51:1376-1382.
8. 1 in vivo. Cell 1998;93:1159-1170.
9. Yee JA, Yan L, Dominguez JC. Allan EH, Martin TJ: Plasminogen-dependent activation of latent transforming growth factor beta (TGF-beta) by growing cultures of osteoblast-like cells. J Cell Physiol 1993;157:528-534.
10. Sato Y, Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-beta1-like molecule by plasmin during co-culture. J Cell Biol 1989;109:309-315.
11. Nikol S, Ramee SR, Benenati JF, Leclerc G, Weir L: Transforming growth factor-beta1 expression is significantly increased in saphenous vein graft with multiple versus single restenosis events (abstract). Circulation 1992;86(suppl):1-21.
12. Nikol S, Weir L, Sullivan A, Sharaf B, White CJ, Zemel G, Hartzler G, Stack R, Leclerc G, Isner JM: Persistently increased expression of the transforming growth factor-beta1 gene in human vascular restenosis: Analysis of 62 patients with one or more episodes of restenosis. Cardiovasc Pathol 1994;3:57-64.
13. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L: Expression of transforming growth factor-beta1 is increased in human vascular restenosis lesions. J Clin Invest 1992;90:1582-1592.
14. Schmidt A, Gopfert C, Vlodavsky I, Volker W, Buddecke E: Induction of a hypertrophic growth status of coronary smooth muscle cells is associated with an overexpression of TGF-beta. Eur J Cell Biol 2002;81:138-144.
15. Morisaki N, Kawano M, Koyama N, Koshikawa T, Umemiya K, Saito Y, Yoshida S: Effects of transforming growth factor-beta1 on growth of aortic smooth muscle cells: Influences of interaction with growth factors, cell state, cell phenotype, and cell cycle. Atherosclerosis 1991;88:227-234.
16. Mii S, Ware JA, Kent KC: Transforming growth factor-beta inhibits human vascular smooth muscle cell growth and migration. Surgery 1993;114:464-470.
17. Lehmann-Bruinsma K, Higley H, Powell JS: Transforming growth factor beta2 (TGF-beta2) suppression of smooth muscle cell (SMC) proliferation after balloon angioplasty of rat carotid arteries (abstract). Clin Res 1994;42:4A.
18. Kingston PA, Sinha S, Appleby CE, David A, Verakis T, Castro MG, Lowenstein PR, Heagerty AM: Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. Circulation 2003;108:2819-2825.
19. Wolf YG, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-beta1 suppresses intimai hyperplasia in a rat model. J Clin Invest 1994;93:1172-1178.
20. Kanzaki T, Tamura K, Takahashi K, Saito Y, Akikusa B, Oohashi H, Kasayuki N, Ueda M, Morisaki N: In vivo effect of TGF-beta 1. Enhanced intimal thickening by administration of TGF-beta 1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol 1995;15:1951-1957.
21. Su JZ, Fukuda N, Hu WY, Kanmatsuse K: Ribozyme to human TGF-beta1 mRNA inhibits the proliferation of human vascular smooth muscle cells. Biochem Biophys Res Commun 2000;278:401-407.
22. Ando H, Fukuda N, Kotani M, Yokoyama S, Kunimoto S, Matsumoto K, Saito S, Kanmatsuse K, Mugishima H: Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta1 mRNA inhibits neointima formation in rat carotid artery after balloon injury. Eur J Pharmacol 2004;483:207-214.
23. Choi KS, Lim IK, Brady JN, Kim SJ: ICE-like protease (caspase) is involved in transforming growth factor beta1-mediated apoptosis in FaO rat hepatoma cell line. Hepatology 1998;27:415-421.
24. Ohta S, Yanagihara K, Nagata K: Mechanism of apoptotic cell death of human gastric carcinoma cells mediated by transforming growth factor beta. Biochem J 1997;324:777-782.
25. Yu Q, Stamenkovic I: Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival. Clin Exp Metastasis 2004;21:235-242.
26. Herbert JM, Carmeliet P: Involvement of u-PA in the anti-apoptotic activity of TGFbeta for vascular smooth muscle cells. FEBS Lett 1997;413:401-404.
27. 1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci USA 1998;95:6983-6988.
28. Vassalli JD, Belin D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987;214:187-191.
29. Pederson DC, Bowyer DE: Endothelial injury and healing in vitro: Studies using an organ culture system. Am J Pathol 1985;119:264-272.
30. Cho A, Mitchell L, Koopmans D, Langille BL: Effects of changes in blood flow rate on cell death and cell proliferation in carotid arteries of immature rabbits. Circ Res 1997;81:328-337.
31. George SJ, Johnson JL, Smith MA, Jackson CL: Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein. J Vasc Res 2001;38:492-501.